- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07761832
Hemoglobin Trends as a Predictor of Outcomes in Critically Ill Patients (The TRENT-ICU Study)
The TRENT-ICU Study (Transfusion Threshold Based on Hemoglobin Trends): Hemoglobin Drop Rate as a Predictor of Adverse Clinical Outcomes in Critically Ill Patients
The goal of this observational study is to evaluate if early absolute hemoglobin decline (during the first 24 hours of admission) can predict prolonged intensive care unit stay (8 days or more) and in-hospital mortality in critically ill adult patients.
The main questions it aims to answer are:
Does absolute hemoglobin decline during the first 24 hours of admission independently predict prolonged intensive care unit stay in critically ill adult patients?
Does absolute hemoglobin decline during the first 24 hours of admission independently predict in-hospital mortality in critically ill adult patients?
Participants will:
Have their routine clinical and laboratory data reviewed retrospectively from their electronic health records (including baseline hemoglobin and a second hemoglobin determination approximately 24 hours after admission). No additional interventions or extra blood draws will be performed beyond routine clinical care.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Querétaro
-
Querétaro City, Querétaro, Mexiko, 76000
- Hospital H+ Querétaro, Santiago de Querétaro, Querétaro
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Adult patients (aged 18 years or older) admitted to the Intensive Care Unit (ICU) between January 2024 and January 2026.
- ICU length of stay greater than 48 hours.
- At least two hemoglobin determinations obtained with an interval of approximately 24 hours apart during routine medical care.
Exclusion Criteria:
- Massive bleeding upon ICU admission.
- Massive transfusion protocol activation.
- Pregnancy.
- Hemoglobinopathies.
- Active hemolytic anemia.
- Medical records with insufficient information for analysis.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Critically Ill Adult Patients
Adult patients admitted to the intensive care unit with an ICU stay of more than 48 hours and at least two hemoglobin determinations obtained approximately 24 hours apart during routine care.
|
Measurement of the absolute difference in hemoglobin concentration (g/dL) between baseline ICU admission and approximately 24 hours post-admission.
Data was collected retrospectively from electronic health records.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Prolonged Intensive Care Unit Stay
Tidsram: From ICU admission up to 28 days
|
Incidence of prolonged intensive care unit (ICU) length of stay, defined a priori as an ICU stay equal to or greater than 8 days.
|
From ICU admission up to 28 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
In-Hospital Mortality
Tidsram: From ICU admission up to 30 days
|
Incidence of all-cause mortality recorded at hospital discharge.
|
From ICU admission up to 30 days
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CEI2026-30/04/V1
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .